ArticleBMC cancer2026
Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChemoresistance remains a major barrier in hepatocellular carcinoma (HCC) treatment, and research on personalized therapies for resistant patients is still nascent. This study aimed to construct a preliminary gene-drug resistance map for HCC to advance research in personalized treatment. PATIENTS AND
methodsTumor tissues from 51 HCC patients who underwent surgical resection at the First Affiliated Hospital of Chongqing Medical University (December 2019 to June 2021) were used to establish in vitro models. High-throughput drug sensitivity screening (HDSS) and whole-exome sequencing (WES) were performed to identify key resistance-associated genes. Integrated analysis with TCGA database data generated a pharmacogenomic atlas of HCC.
resultsMutational frequencies of key oncogenes and tumor suppressor genes in HCC patients were elevated and largely consistent with The Cancer Genome Atlas (TCGA) data. FAT4 mutations were significantly associated with resistance to epirubicin, doxorubicin, 5-fluorouracil, and XELOX regimens (p < 0.05). KMT2D mutations showed significant correlations with resistance to gemcitabine, 5-FU + cisplatin, ADM + L-OHP, and L-OHP + irinotecan (p < 0.05). PABPC1 mutations were linked to resistance in doxorubicin, apatinib, and ADM + L-OHP regimens (p < 0.05).
conclusionsFAT4, KMT2D, and PABPC1 are potential key drivers of chemoresistance in HCC, demonstrating cross-regimen associations. These findings may inform personalized chemotherapy strategies for advanced HCC, although further clinical validation is warranted.
trial registrationThis study was registered at the Chinese Clinical Trial Registry ( https://www.chictr.org.cn ; registration number: ChiCTR1900022193; registration date: 2019/03/30).Observational Study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.